Barclays cut BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) price target from $125 to $105. BioMarin Pharmaceutical shares closed at $88.36 on Monday.
SunTrust Robinson Humphrey lowered the price target on Penntex Midstream Partners...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to United Therapeutics (UTHR):